Abstract:Background: This study aims to explore the variations of hepatic vascular geometries in patients with clinically significant portal hypertension (CSPH) and investigate the capability of using CT/MRI angiographic imaging-based vascular geometrical model (VGM) to identify CSPH patients. Methods: A total of 64 vascular geometrical parameters were extracted from the portal vein (PV), hepatic vein (HV), aorta and inferior vena cava and then fed into a VGM for identification of CSPH patients. A total of 853 consecutive liver cirrhosis patients from 3 medical centers who underwent contrast-enhanced imaging within 14 days of transjugular catheterization for hepatic venous pressure gradient (HVPG) were included. The VGM model was trained and validated on a CT cohort containing 256 cirrhosis patients and 202 age-matched participants without a history of chronic liver diseases, and tested on both CT and MR cohorts. Findings: Significant reduction of whole vessel volumes were observed in both PV (from 36·90±15·99 to 29·61±11·07 cm3) and HV (from 35·28±21·47 to 22·44±15·65 cm3) when CSPH occurred. Similarly, whole vessel lengths were reduced in CSPH patients in both PV (from 3·00±2·37 to 1·72±1·23 m) and HV (from 1·83±1·48 to 0·91±1·51 m). The number of external associations of vessel parameters (defined as R>0·5) increased when CSPH occurred, which verified the derangement of the vascular system in the liver. The performance of VGM outperformed conventional clinical models significantly in both internal and external validation cohorts. Interpretation: This study developed and validated a contrast-enhanced CT/MRI-based VGM with good diagnostic consistency to the HVPG measurement, which shows good potential for clinical applications.Trial Registration: We conducted this study using the database of a CT cohort (CHESS1701; ClinicalTrials.gov identifier: NCT03138915) between August 2016 and September 2017 and a MR cohort (CHESS1802; ClinicalTrials.gov identifier: NCT03766880) from December 2018 toApril 2019.Funding: This study was funded by the National Natural Science Foundation of China (No. 81971583, No. 62001120), National Key R&D Program of China (No. 2018YFC1312900, No. 2019YFA0709502), Science Fund for Distinguished Young Scholars (No. 20JR10RA713), Shanghai Natural Science Foundation (No. 20ZR1406400), Shanghai Municipal Science and Technology Major Project (No.2017SHZDZX01, No.2018SHZDZX01), Shanghai Municipal Science and Technology (No.17411953600), Shanghai Sailing Program (No. 20YF1402400), ZJLab and Key Laboratory of Computational Neuroscience and BrainInspired Intelligence (Fudan University), Ministry of Education, China.Declaration of Interest: The authors declare no conflict of interest.Ethical Approval: The study was in agreement with the ethical guidelines of the 1975 Declaration ofHelsinki and approved by the Ethics Committee of the Fifth Medical Center at PLAGeneral Hospital. The requirement for informed consent was waived.

Feasibility Study: Magnetic Compressed Extrahepatic Portal-Systemic Shunt in Cadaver

Surgical Treatment of Portal Vein Cavernous Transformation

Separate control of the splenic artery and vein in laparoscopic splenectomy and pericardial devascularization for the treatment of portal hypertension

Ventriculoatrial Shunt As a Feasible Regimen for Certain Patients of Hydrocephalus: Clinical Features and Surgical Management

Case Report: Early detection and intervention of congenital portosystemic shunts in children

Status of transjugular intrahepatic portosystemic shunt for portal hypertension in China: A national survey analysis

Status of transjugular intrahepatic portosystemic shunt for portal hypertension in China:A national survey analysis

[Comparative study of expression of p21 and c-myc protein in hepatocellular carcinoma with pericarcinomatous liver tissue].

Hemodynamic study of portal hypertension

The effect of distal splenorenal shunt in treatment of portal hypertension

A Clinical Study on Side-to-side Portacaval Shunt Plus Enhancement of Perfusion of Hepatic Artery

Activation of src family kinase lck following CD28 crosslinking in the Jurkat leukemic cell line.

Utilizing a suture-constrained covered stent for shunt reduction to treat transjugular intrahepatic portosystemic shunt-related refractory hepatic encephalopathy: a retrospective study

Unveiling the impact of cirrhotic cardiomyopathy on portal hemodynamics and survival after transjugular intrahepatic portosystemic shunt: a prospective study

A new computational fluid dynamics based noninvasive assessment of portacaval pressure gradient

S4362 Hepatic Portosystemic Shunts in Non-Cirrhotic Patients on CT: A Case Series

80 SAFETY AND TOLERABILITY OF HUMAN MESENCHYMAL STEM CELLS FOR PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS: A PRELIMINARY STUDY

Development and Validation of a Hepatic Vascular Geometrical Model for Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)

Investigation of Minibleeding Pericardial Vascular Disconnection with Curved Cutter Stapler in Patients of Portal Hypertension

Central Shunt Procedures for Complex Congenital Heart Diseases.

Impact of portal flow on the prognosis of children with congenital portosystemic shunt: A multicentric observation study in Japan